Provided is a kit for detecting Neisseria gonorrhoeae in a sample, as a novel Neisseria gonorrhoeae detection means that has superior Neisseria gonorrhoeae detection sensitivity and can detect Neisseria gonorrhoeae in situ from a variety of samples, such as urine or intraoral fluid. This kit includes a capture antibody that is for capturing a Neisseria gonorrhoeae-originating antigen in a sample, and a detection antibody that has a detection marker and is for marking the Neisseria gonorrhoeae-originating antigen in the sample. The Neisseria gonorrhoeae-originating antigen is a Neisseria gonorrhoeae ribosomal protein L7/L12. One of the capture antibody and the detection antibody is a first monoclonal antibody or a fragment or derivative thereof that produces an antigen-antibody reaction with an epitope including one or more amino acid residues selected from the second to 14th amino acid residues from the N-terminus in the Neisseria gonorrhoeae L7/L12 amino acid sequence indicated in SEQ ID NO:1. The other of the capture antibody and the detection antibody is a second monoclonal antibody or a fragment or derivative thereof that produces an antigen-antibody reaction with an epitope including one or more amino acid residues selected from the 102nd to 123rd amino acid residues from the N-terminus in the Neisseria gonorrhoeae L7/L12 amino acid sequence indicated in SEQ ID NO:1.

Provided is a kit for detecting Neisseria gonorrhoeae in a sample, as a novel Neisseria gonorrhoeae detection means that has superior Neisseria gonorrhoeae detection sensitivity and can detect Neisseria gonorrhoeae in situ from a variety of samples, such as urine or intraoral fluid. This kit includes a capture antibody that is for capturing a Neisseria gonorrhoeae-originating antigen in a sample, and a detection antibody that has a detection marker and is for marking the Neisseria gonorrhoeae-originating antigen in the sample. The Neisseria gonorrhoeae-originating antigen is a Neisseria gonorrhoeae ribosomal protein L7/L12. One of the capture antibody and the detection antibody is a first monoclonal antibody or a fragment or derivative thereof that produces an antigen-antibody reaction with an epitope including one or more amino acid residues selected from the second to 14th amino acid residues from the N-terminus in the Neisseria gonorrhoeae L7/L12 amino acid sequence indicated in SEQ ID NO:1. The other of the capture antibody and the detection antibody is a second monoclonal antibody or a fragment or derivative thereof that produces an antigen-antibody reaction with an epitope including one or more amino acid residues selected from the 102nd to 123rd amino acid residues from the N-terminus in the Neisseria gonorrhoeae L7/L12 amino acid sequence indicated in SEQ ID NO:1.

Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.

Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.

This invention relates, inter alia, to an immunogenic fragment of a Neisserial Heparin Binding Antigen (NHBA) protein of Neisseria gonorrhoeae (SEQ ID NO: 1) for the prevention and treatment of Neisseria gonorrhoeae or gonococcal- or meningococcal-associated diseases and conditions. In some embodiments, the immunogenic fragment corresponds to a C-terminal fragment of the protein (SEQ ID NO: 2).

A device for optical biosensing using magnetic particles includes an optical waveguide at least a light source at the input of the optical waveguide, an evanescent field generated at the exterior surface with an effective range, a plurality of magnetic particles tethered to the exterior surface, a magnetic field generator, the magnetic field generator configured to alternate between a first state in which the plurality of magnetic particles extend outside of the effective range and a second state in which the plurality of magnetic particles do not extend outside of the effective range, a capture reagent disposed on the exterior surface that holds a first quantity of magnetic particles within the effective range when the magnetic field generator is in the second state and an analyte of interest is present, and a second quantity when not, producing a first output signal and a second output signal respectively.

A device for optical biosensing using magnetic particles includes an optical waveguide at least a light source at the input of the optical waveguide, an evanescent field generated at the exterior surface with an effective range, a plurality of magnetic particles tethered to the exterior surface, a magnetic field generator, the magnetic field generator configured to alternate between a first state in which the plurality of magnetic particles extend outside of the effective range and a second state in which the plurality of magnetic particles do not extend outside of the effective range, a capture reagent disposed on the exterior surface that holds a first quantity of magnetic particles within the effective range when the magnetic field generator is in the second state and an analyte of interest is present, and a second quantity when not, producing a first output signal and a second output signal respectively.